What We Can Learn From Bill Ackman Walking Away From Valeant Pharmaceuticals Intl Inc.

Investors can learn a lot from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

| More on:
The Motley Fool

Recently, it was announced that hedge fund manager Bill Ackman sold his firm’s entire stake in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). By selling his final position, he has done what many investors hate to do: he locked in losses.

Almost every investor has at least one position in their portfolio that is held at a loss. When an investor enters a position and sees the investment decline in value by say 20%, it is important to understand what needs to happen for the investor to be able to recoup their original investment. Using very simple math, an investment of $100 which declines by 20% to $80 needs to return to $100 for the investor to be even.

Assuming we hit the reset button here, a new investor may purchase the shares at $80 and get a $20 return divided by the initial outlay of $80, which translates to a return of 25%, not 20%!

For investors holding positions that are slightly at a loss, the amount a stock must come back to make up the loss is nothing more than a rounding error. Once it gets beyond 20-25%, however, the numbers are a little more serious.

With a loss of 10% as an example, the return must be 10/90 = 11.1%, meaning a difference of 1.1% — a very minor number.

Valeant shares have declined close to 90% since Ackman made the initial investment, translating to a return of (90/10) = 900% for his firm to get back to even. Although we’ve seen the hedge fund manager do fantastic things in the past, any investor hoping for a return of 900% is dreaming.

The amount of interest expenses as a percentage of revenue is simply too high for this company to survive over the long term, translating to a desperate need to either drastically increase revenue or repay debt.

As it is difficult to increase revenues, the second option is to pay off debt. Debt is close to $30 billion, and that can only mean selling assets or doing a secondary share issue. The challenge with this possibility is that Valeant has $30 billion in debt but a market capitalization of only approximately $5 billion. If the float were to double, the debt would only be reduced by approximately 16.5% or so.

And it seems the company is in for the fight of a lifetime after losing one of the heavyweight members of the board of directors.

Although the company has many excellent products to offer consumers, the reality is, the debt burden is simply too much to carry at this point. Bankruptcy may take months from here, but it’s inevitable — the fat lady will sing!

Fool contributor Ryan Goldsman has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Piggy bank wrapped in Christmas string lights
Investing

TFSA: 2 TSX Stocks for Your $7,000 Contribution

These two companies, with proven track records and healthy long-term growth potential, are ideal additions to your TFSA.

Read more »

man makes the timeout gesture with his hands
Energy Stocks

Think U.S. Stocks Are Overvalued? Invest Smart and Buy These Canadian Ones Instead

If you’ve been watching U.S. stocks this year, you’ve probably felt like you were strapped into a rollercoaster ride. One…

Read more »

diversification and asset allocation are crucial investing concepts
Tech Stocks

Here Are My Top 2 Tech Stocks to Buy Now

Investors looking for two world-class tech stocks to buy today for big gains over the long term do have prime…

Read more »

Two seniors walk in the forest
Retirement

Retiring in Canada? Create $1,000 a Month in Dividend Income to Supplement CPP

Dividend income can be a meaningful part of your retirement plan, helping supplement your CPP and OAS. Here's how.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Monday, December 15

The TSX may open higher today as metals rally, but broader sentiment could hinge on whether Canadian inflation cools further…

Read more »

man looks surprised at investment growth
Dividend Stocks

This 6% Dividend Stock Pays Cash Every Single Month

Given its strong financial position and solid growth prospects, Whitecap appears well-equipped to reward shareholders with higher dividend yields, making…

Read more »

Dividend Stocks

1 Canadian Dividend Stock Down 33% Every Investor Should Own

A freight downturn has knocked TFI International’s stock, but its discipline and safe dividend could turn today’s dip into tomorrow’s…

Read more »

Person holds banknotes of Canadian dollars
Dividend Stocks

The 7.3% Dividend Gem Every Passive-Income Investor Should Know About

Buying 1,000 shares of this TSX stock today would generate about $154 per month in passive income based on its…

Read more »